1. Market Research
  2. > All Companies
  3. > Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies

There are more than 1400 sustained or controlled release drugs approved all over the world. Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of generics is approximately 20% of the overall international pharmaceutical market. Utilization of generic in terms of volume is higher in the US and lower in Japan, 89% and 24% respectively.
The oral drug delivery market remains the largest slice of the overall drug delivery market, with more than 52% of market share. It is presently valued at $49 billion and is expected to reach over $90 billion by 2016, at a CAGR of 11%. The growth in the oral drug delivery market shall be driven primarily by newer technologies enabling controlled release formulations of oral drugs and oral formulations of injectable only drugs. Global injectable drug delivery market is expected to be worth $29b by 2015.

Novel drug delivery systems (NDDS) offer many more advantages, which include improved therapy by increasing the efficacy and duration of drug activity, increased patient compliance through decreased dosing frequency and convenient routes of administration, and improved targeting for a specific site to reduce unwanted side effects. The challenge for both drug and drug delivery companies is to deliver both existing and emerging drug technologies in a manner that improves the current benefits enjoyed by the patients.

The generic market with reference to innovative molecule (NCE) has become very competitive as several companies have already filed ANDA's for potential generic drugs in the near term. The study of the novel drug delivery companies and their formulation technologies will provide the potential value added opportunity in the generic field in terms of patient’s compliance or bioavailability enhancement. It will also provide an enhanced life cycle for drugs under patent coverage (life cycle extension).

This comprehensive report on novel drug delivery system focuses mainly on the oral and injectable formulations of pharmaceuticals and specialty companies. This report enumerates the various formulation technologies involved in making value added formulations, pharmaceutical applications and advantages of specific technologies. Wherever possible, marketed drugs using a similar technology have been discussed as proof of validation along with the status of additional pipeline. The discussed proprietary formulation technologies includes Colal, Glide SDI, Arestat, GeoClock, GeoMatrix, FlashTab, Lock Tab, Medusa, Eligen, Oradur, EnteriCare and Saber.

This report will be helpful for those pharma companies who are exploring novel opportunities for their growth by in-licensing formulation technology or value added pipeline drugs available/being studied in the market.

Table Of Contents

Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Unilife Corporation (UNIS) - Product Pipeline Analysis, 2014 Update

Unilife Corporation (UNIS) - Product Pipeline Analysis, 2014 Update

  • $ 750
  • Company report
  • October 2014
  • by Global Data

Summary Unilife Corporation (Unilife) is a developer and commercial supplier of injectable drug delivery systems. It carries out the design, development, manufacture and distribution of safety engineered ...

Pathfinder Cell Therapy, Inc. (PFND) - Financial and Strategic SWOT Analysis Review

Pathfinder Cell Therapy, Inc. (PFND) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • July 2015
  • by Global Data

Summary Pathfinder Cell Therapy, Inc. (Pathfinder Cell Therapy) is a regenerative medicine company. The company’s services include cell therapy. Its cell therapy is developing a novel cell-based therapy ...

Parenteral Drug India Ltd. (PDPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Parenteral Drug India Ltd. (PDPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2015
  • by Global Data

Summary Parenteral Drugs (India) Limited (Parenteral Drugs) is a pharmaceutical company. The company discovers, researches, develops and manufactures pharmaceutical products. Its products include solid ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.